Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

American Journal of Gastroenterology

Volumn 110, Issue 9, 2015, Pages 1324-1338

  Peyrin Biroulet, L ^a   Sandborn, W ^b   Sands, B E ^c   Reinisch, W ^d,e   Bemelman, W ^f   Bryant, R V ^g   D'Haens, G ^f   Dotan, I ^h   Dubinsky, M ^c   Feagan, B ⁱ   Fiorino, G ^j   Gearry, R ^k   Krishnareddy, S ^l   Lakatos, P L ^m   Loftus, E V ⁿ   Marteau, P ^o   Munkholm, P ^p   Murdoch, T B ^q   Ordas I ^r   Panaccione, R ^s   Riddell, R H ^t   Ruel, J ^u   Rubin, D T ^v   Samaan, M ^f   Siegel, C A ^w   Silverberg, M S ^t   Stoker, J ^x   Schreiber, S ^y   Travis, S ^g   Van Assche, G ^q,z   Danese, S ^j   Panes, J ^r   Bouguen, G ^aa   O'Donnell, S ^t   Pariente, B ^ab   Winer, S ^ac   Hanauer, S ^ad   Colombel, J F ^c   more..

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d MCMASTER UNIVERSITY   (Canada)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^h TEL AVIV UNIVERSITY   (Israel)

ⁱ UNIVERSITY OF WESTERN ONTARIO   (Canada)

^j HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^k UNIVERSITY OF OTAGO   (New Zealand)

^l Och Spine at New York Presbyterian Hospitals   (United States)

^m SEMMELWEIS UNIVERSITY   (Hungary)

ⁿ MAYO CLINIC   (United States)

^o ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^p UNIVERSITY OF COPENHAGEN   (Denmark)

^q UNIVERSITY OF TORONTO   (Canada)

^r INSTITUTO DE SALUD CARLOS III   (Spain)

^s UNIVERSITY OF CALGARY   (Canada)

^t MOUNT SINAI HOSPITAL   (Canada)

^u CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^v UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^w Dartmouth Hitchcock Inflammatory Bowel Disease Center   (United States)

^x UNIVERSITY OF AMSTERDAM   (Netherlands)

^y UNIVERSITY OF KIEL   (Germany)

^z UNIVERSITY OF LEUVEN   (Belgium)

^aa UNIVERSITÉ DE RENNES 1   (France)

^ab UNIV LILLE   (France)

^ac UNIVERSITY OF TORONTO   (Canada)

^ad NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CALGRANULIN; INFLIXIMAB;

ABDOMINAL PAIN; ARTICLE; CLINICAL PRACTICE; CONSENSUS; CROHN DISEASE; DEFECATION HABIT; DIARRHEA; EVIDENCE BASED PRACTICE; HUMAN; INFLAMMATORY BOWEL DISEASE; PATIENT ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; RECTUM HEMORRHAGE; REMISSION; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; DISEASE MANAGEMENT; INFLAMMATORY BOWEL DISEASES; PRACTICE GUIDELINE; PROCEDURES;

DISEASE MANAGEMENT; HUMANS; INFLAMMATORY BOWEL DISEASES; PRACTICE GUIDELINES AS TOPIC; REMISSION INDUCTION;

EID: 84941260661     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.233     Document Type: Article

References (176)

1. Bernstein CN, Loftus EV Jr., Ng SC et al. Hospitalisations and surgery in Crohn's disease. Gut 2012; 61: 622-9.
2. Peyrin-Biroulet L, Loftus EV Jr., Colombel JF et al. Th e natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010; 105: 289-97.
3. Peyrin-Biroulet L, Loftus EV Jr., Colombel JF et al. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. Infl amm Bowel Dis 2011; 17: 471-8.
4. Magro F, Rodrigues A, Vieira AI et al. Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts. Infl amm Bowel Dis 2012; 18: 573-83.
5. Torres J, Billioud V, Sachar DB et al. Ulcerative colitis as a progressive disease: the forgotten evidence. Infl amm Bowel Dis 2012; 18: 1356-63.
6. Frolkis AD, Dykeman J, Negron ME et al. Risk of surgery for infl ammatory bowel diseases has decreased over time: a systematic review and metaanalysis of population-based studies. Gastroenterology 2013; 145: 996-1006.
7. Jess T, Simonsen J, Jorgensen KT et al. Decreasing risk of colorectal cancer in patients with infl ammatory bowel disease over 30 years. Gastroenterology 2012; 143: 375-81.
8. Vester-Andersen MK, Prosberg MV, Jess T et al. Disease course and surgery rates in infl ammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy. Am J Gastroenterol 2014; 109: 705-14.
9. Pariente B, Cosnes J, Danese S et al. Development of the Crohn's disease digestive damage score, the Lemann score. Infl amm Bowel Dis 2011; 17: 1415-22.
10. Peyrin-Biroulet L, Cieza A, Sandborn WJ et al. Development of the fi rst disability index for infl ammatory bowel disease based on the international classifi cation of functioning, disability and health. Gut 2012; 61: 241-7.
11. Peyrin-Biroulet L, Bressenot A, Kampman W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? Clin Gastroenterol Hepatol 2014; 12: 929-34.
12. Sandborn WJ, Hanauer S, Van Assche G et al. Treating beyond symptoms with a view to improving patient outcomes in infl ammatory bowel diseases. J Crohns Colitis 2014; 8: 927-35.
13. Mosli MH, Feagan BG, Sandborn WJ et al. Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. Infl amm Bowel Dis 2014; 20: 564-75.
14. Jurgens M, Mahachie John JM, Cleynen I et al. Levels of C-reactive protein are associated with response to infl iximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011; 9: 421-7.
15. Lewis JD. Th e utility of biomarkers in the diagnosis and therapy of infl ammatory bowel disease. Gastroenterology 2011; 140: 1817-26.
16. D'Haens G, Ferrante M, Vermeire S et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in infl ammatory bowel disease. Infl amm Bowel Dis 2012; 18: 2218-24.
17. Williet N, Sandborn WJ, Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of infl ammatory bowel disease. Clin Gastroenterol Hepatol 2014; 12: 1246-56.
18. Pincus T, Gibofsky A, Weinblatt ME. Urgent care and tight control of rheumatoid arthritis as in diabetes and hypertension: better treatments but a shortage of rheumatologists. Arthritis Rheum 2002; 46: 851-4.
19. Bouguen G, Levesque BG, Feagan BG et al. Treat to target: a proposed new paradigm for the management of Crohn's disease. Clin Gastroenterol Hepatol 2013, S1542-S3565.
20. Rachmani R, Slavacheski I, Berla M et al. Treatment of high-risk patients with diabetes: motivation and teaching intervention: a randomized, prospective 8-year follow-up study. J Am Soc Nephrol 2005; 16: S22-6.
21. Eeg-Olofsson K, Cederholm J, Nilsson PM et al. Glycemic and risk factor control in type 1 diabetes: results from 13,612 patients in a national diabetes register. Diabetes Care 2007; 30: 496-502.
22. Patel A, MacMahon S, Chalmers J et al. Eff ects of a fi xed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-40.
23. Pearson TA. Th e epidemiologic basis for population-wide cholesterol reduction in the primary prevention of coronary artery disease. Am J Cardiol 2004; 94: 4f-8f.
24. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.
25. Mora S, Musunuru K, Blumenthal RS. Th e clinical utility of highsensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines. Clin Chem 2009; 55: 219-28.
26. Pariente B, Cosnes J, Danese S et al. Development of the Crohn's disease digestive damage score, the Lemann score. Infl amm Bowel Dis 2011; 17: 1415-22.
27. Best WR, Becktel JM, Singleton JW et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-44.
28. Th ia KT, Sandborn WJ, Lewis JD et al. Defi ning the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease. Am J Gastroenterol 2008; 103: 3123-31.
29. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980; 1: 514.
30. Vermeire S, Schreiber S, Sandborn WJ et al. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol 2010; 8: 357-63.
31. Hyams JS, Ferry GD, Mandel FS et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991; 12: 439-47.
32. Turner D, Mack D, Leleiko N et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology 2010; 138: 2282-91.
33. Peyrin-Biroulet L, Reinisch W, Colombel JF et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut 2014; 63: 88-95.
34. Jones J, Loftus EV Jr., Panaccione R et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008; 6: 1218-24.
35. Modigliani R, Mary JY, Simon JF et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Th erapeutique des Aff ections Infl ammatoires Digestives. Gastroenterology 1990; 98: 811-8.
36. Levesque BG, Sandborn WJ, Ruel J et al. Converging goals of treatment of infl ammatory bowel disease from clinical trials and practice. Gastroenterology 2015; 148: 37-51.
37. Colombel JF, Sandborn WJ, Reinisch W et al. Infl iximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
38. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
39. Panaccione R, Colombel JF, Sandborn WJ et al. Adalimumab maintains remission of Crohn's disease aft er up to 4 years of treatment: data from CHARM and ADHERE. Aliment Pharmacol Th er 2013; 38: 1236-47.
40. Daperno M, D'Haens G, Van Assche G et al. Development and validation of a new, simplifi ed endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004; 60: 505-12.
41. Khanna R, Zou G, D'Haens G et al. Reliability among central readers in the evaluation of endoscopic fi ndings from patients with Crohn's disease. Gut; advance online publication, 2 May 2015 [e-pub ahead of print].
42. Sipponen T, Savilahti E, Karkkainen P et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Infl amm Bowel Dis 2008; 14: 1392-8.
43. Sipponen T, Savilahti E, Kolho KL et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic fi ndings. Infl amm Bowel Dis 2008; 14: 40-6.
44. Smith JP, Bingaman SI, Ruggiero F et al. Th erapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial. Dig Dis Sci 2011; 56: 2088-97.
45. Ferrante M, Colombel JF, Sandborn WJ et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology 2013; 145: 978-86.
46. Ferrante M, de Hertogh G, Hlavaty T et al. Th e value of myenteric plexitis to predict early postoperative Crohn's disease recurrence. Gastroenterology 2006; 130: 1595-606.
47. Gecse K, Lowenberg M, Bossuyt P et al. Sa1198 Agreement among experts in the endoscopic evaluation of postoperative recurrence in Crohn's disease using the Rutgeerts score. Gastroenterology 2014; 146: S-227.
48. Reinisch W, Angelberger S, Petritsch W et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: effi cacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 2010; 59: 752-9.
49. Baert F, Moortgat L, Van Assche G et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010; 138: 463-8.
50. Colombel JF, Rutgeerts P, Reinisch W et al. Early mucosal healing with infl iximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141: 1194-201.
51. De Cruz P, Kamm MA, Prideaux L et al. Mucosal healing in Crohn's disease: a systematic review. Infl amm Bowel Dis 2013; 19: 429-44.
52. D'Haens G, Baert F, van Assche G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-7.
53. Neurath MF, Travis SP. Mucosal healing in infl ammatory bowel diseases: a systematic review. Gut 2012; 61: 1619-35.
54. Rutgeerts P, Diamond RH, Bala M et al. Scheduled maintenance treatment with infl iximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006; 63: 433-42.
55. Schnitzler F, Fidder H, Ferrante M et al. Mucosal healing predicts longterm outcome of maintenance therapy with infl iximab in Crohn's disease. Infl amm Bowel Dis 2009; 15: 1295-301.
56. Bryant RV, Winer S, Travis SP et al. Systematic review: histological remission in infl ammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative. J Crohns Colitis 2014; 8: 1582-97.
57. Goldman H, Antonioli DA. Mucosal biopsy of the rectum, colon, and distal ileum. Hum Pathol 1982; 13: 981-1012.
58. Langner C, Magro F, Driessen A et al. Th e histopathological approach to infl ammatory bowel disease: a practice guide. Virchows Arch 2014; 464: 511-27.
59. Magro F, Langner C, Driessen A et al. European consensus on the histopathology of infl ammatory bowel disease. J Crohns Colitis 2013; 7: 827-51.
60. Geboes K, Riddell R, Ost A et al. A reproducible grading scale for histological assessment of infl ammation in ulcerative colitis. Gut 2000; 47: 404-9.
61. Ordas I, Rimola J, Rodriguez S et al. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease. Gastroenterology 2014; 146: 374-82.
62. Panes J, Bouhnik Y, Reinisch W et al. Imaging techniques for assessment of infl ammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis 2013; 7: 556-85.
63. Panes J, Bouzas R, Chaparro M et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. Aliment Pharmacol Th er 2011; 34: 125-45.
64. Siddiki HA, Fidler JL, Fletcher JG et al. Prospective comparison of stateof-the-art MR enterography and CT enterography in small-bowel Crohn's disease. AJR Am J Roentgenol 2009; 193: 113-21.
65. Solem CA, Loftus EV Jr., Fletcher JG et al. Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc 2008; 68: 255-66.
66. Ordas I, Rimola J, Rodriguez S et al. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease. Gastroenterology 2014; 146: 374-82.
67. Rimola J, Ordas I, Rodriguez S et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Infl amm Bowel Dis 2011; 17: 1759-68.
68. Rimola J, Rodriguez S, Garcia-Bosch O et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease. Gut 2009; 58: 1113-20.
69. Bosch OG, Ordas I, Rodriguez S et al. 90 Comparison of the impact of MRI and colonoscopy on management of Crohn's disease. Gastroenterology 2012; 142: S-21-2.
70. Bruining DH, Loftus EV Jr., Ehman EC et al. Computed tomography enterography detects intestinal wall changes and eff ects of treatment in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011; 9: 679-83.
71. Bruining DH, Siddiki HA, Fletcher JG et al. Benefi t of computed tomography enterography in Crohn's disease: eff ects on patient management and physician level of confi dence. Infl amm Bowel Dis 2012; 18: 219-25.
72. Takenaka K, Ohtsuka K, Kitazume Y et al. Comparison of magnetic resonance and balloon enteroscopic examination of the small intestine in patients with Crohn's disease. Gastroenterology 2014; 147: 334-42.
73. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-33.
74. Kiss LS, Papp M, Lovasz BD et al. High-sensitivity C-reactive protein for identifi cation of disease phenotype, active disease, and clinical relapses in Crohn's disease: a marker for patient classifi cation? Infl amm Bowel Dis 2012; 18: 1647-54.
75. Lamireau T, Cezard JP, Dabadie A et al. Effi cacy and tolerance of infl iximab in children and adolescents with Crohn's disease. Infl amm Bowel Dis 2004; 10: 745-50.
76. Rutgeerts P, D'Haens G, Targan S et al. Effi cacy and safety of retreatment with anti-tumor necrosis factor antibody (infl iximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 761-9.
77. Stack WA, Mann SD, Roy AJ et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 1997; 349: 521-4.
78. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
79. Reinisch W, Wang Y, Oddens BJ et al. C-reactive protein, an indicator for maintained response or remission to infl iximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Th er 2012; 35: 568-76.
80. Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-38.
81. Schreiber S, Rutgeerts P, Fedorak RN et al. A randomized, placebocontrolled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005; 129: 807-18.
82. Louis E, Mary JY, Vernier-Massouille G et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy aft er infl iximab therapy is stopped. Gastroenterology 2012; 142: 63-70.
83. Treton X, Bouhnik Y, Mary JY et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009; 7: 80-5.
84. Florin TH, Paterson EW, Fowler EV et al. Clinically active Crohn's disease in the presence of a low C-reactive protein. Scand J Gastroenterol 2006; 41: 306-11.
85. Pepys MB, Hirschfi eld GM. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-12.
86. Gisbert JP, Bermejo F, Perez-Calle JL et al. Fecal calprotectin and lactoferrin for the prediction of infl ammatory bowel disease relapse. Infl amm Bowel Dis 2009; 15: 1190-8
87. De Cruz P, Kamm MA, Hamilton AL et al. Crohn's disease management aft er intestinal resection: a randomised trial. Lancet 2015; 385: 1406-17.
88. Khanna R, Zou G, D'Haens G et al. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity. Aliment Pharmacol Th er 2015; 41: 77-86.
89. Burisch J, Weimers P, Pedersen N et al. Health-related quality of life improves during one year of medical and surgical treatment in a European population-based inception cohort of patients with infl ammatory bowel disease-an ECCO-EpiCom study. J Crohns Colitis 2014; 8: 1030-42.
90. Drossman DA, Leserman J, Li ZM et al. Th e rating form of IBD patient concerns: a new measure of health status. Psychosom Med 1991; 53: 701-12.
91. Guyatt G, Mitchell A, Irvine EJ et al. A new measure of health status for clinical trials in infl ammatory bowel disease. Gastroenterology 1989; 96: 804-10.
92. Irvine EJ, Feagan B, Rochon J et al. Quality of life: a valid and reliable measure of therapeutic effi cacy in the treatment of infl ammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994; 106: 287-96.
93. Irvine EJ, Zhou Q, Th ompson AK. Th e Short Infl ammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing infl ammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. Am J Gastroenterol 1996; 91: 1571-8.
94. Jenkinson C, Gray A, Doll H et al. Evaluation of index and profi le measures of health status in a randomized controlled trial. Comparison of the Medical Outcomes Study 36-Item Short Form Health Survey, EuroQol, and disease specifi c measures. Med Care 1997; 35: 1109-18.
95. Lonnfors S, Vermeire S, Greco M et al. IBD and health-related quality of life-Discovering the true impact. J Crohns Colitis 2014; 8: 1281-6.
96. Love JR, Irvine EJ, Fedorak RN. Quality of life in infl ammatory bowel disease. J Clin Gastroenterol 1992; 14: 15-19.
97. McColl E, Han SW, Barton JR et al. A comparison of the discriminatory power of the Infl ammatory Bowel Disease Questionnaire and the SF-36 in people with ulcerative colitis. Qual Life Res 2004; 13: 805-11.
98. van der Have M, van der Aalst KS, Kaptein AA et al. Determinants of health-related quality of life in Crohn's disease: a systematic review and meta-analysis. J Crohns Colitis 2014; 8: 93-106.
99. Ware JE Jr., Sherbourne CD. Th e MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-83.
100. Graff LA, Walker JR, Bernstein CN. Depression and anxiety in infl ammatory bowel disease: a review of comorbidity and management. Infl amm Bowel Dis 2009; 15: 1105-18.
101. Mikocka-Walus AA, Turnbull DA, Moulding NT et al. Controversies surrounding the comorbidity of depression and anxiety in infl ammatory bowel disease patients: a literature review. Infl amm Bowel Dis 2007; 13: 225-34.
102. Nahon S, Lahmek P, Durance C et al. Risk factors of anxiety and depression in infl ammatory bowel disease. Infl amm Bowel Dis 2012; 18: 2086-91.
103. Beck AT, Ward CH, Mendelson M et al. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-71.
104. Lichtenstein GR, Bala M, Han C et al. Infl iximab improves quality of life in patients with Crohn's disease. Infl amm Bowel Dis 2002; 8: 237-43.
105. Loftus EV, Feagan BG, Colombel JF et al. Eff ects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol 2008; 103: 3132-41.
106. Loftus EV Jr., Guerin A, Yu AP et al. Increased risks of developing anxiety and depression in young patients with Crohn's disease. Am J Gastroenterol 2011; 106: 1670-7.
107. Minderhoud IM, Samsom M, Oldenburg B. Crohn's disease, fatigue, and infl iximab: is there a role for cytokines in the pathogenesis of fatigue? World J Gastroenterol 2007; 13: 2089-93.
108. Reinisch W, Sandborn WJ, Bala M et al. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Infl amm Bowel Dis 2007; 13: 1135-40.
109. Zhang CK, Hewett J, Hemming J et al. Th e influence of depression on quality of life in patients with infl ammatory bowel disease. Infl amm Bowel Dis 2013; 19: 1732-9.
110. Zigmond AS, Snaith RP. Th e hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-70.
111. Zung WW. Th e Depression Status Inventory: an adjunct to the Self-Rating Depression Scale. J Clin Psychol 1972; 28: 539-43.
112. Beck A, Bager P, Jensen PE et al. How fatigue is experienced and handled by female outpatients with infl ammatory bowel disease. Gastroenterol Res Pract 2013; 2013: 153818.
113. Czuber-Dochan W, Ream E, Norton C. Review article: Description and management of fatigue in infl ammatory bowel disease. Aliment Pharmacol Th er 2013; 37: 505-16.
114. Graff LA, Clara I, Walker JR et al. Changes in fatigue over 2 years are associated with activity of infl ammatory bowel disease and psychological factors. Clin Gastroenterol Hepatol 2013; 11: 1140-6.
115. Jelsness-Jorgensen LP, Bernklev T, Henriksen M et al. Chronic fatigue is associated with increased disease-related worries and concerns in infl ammatory bowel disease. World J Gastroenterol 2012; 18: 445-52.
116. Romberg-Camps MJ, Bol Y, Dagnelie PC et al. Fatigue and health-related quality of life in infl ammatory bowel disease: results from a populationbased study in the Netherlands: the IBD-South Limburg cohort. Infl amm Bowel Dis 2010; 16: 2137-47.
117. Smets EM, Garssen B, Bonke B et al. Th e Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995; 39: 315-25.
118. Tinsley A, Macklin EA, Korzenik JR et al. Validation of the functional assessment of chronic illness therapy-fatigue (FACIT-F) in patients with infl ammatory bowel disease. Aliment Pharmacol Th er 2011; 34: 1328-36.
119. van Langenberg DR, Gibson PR. Factors associated with physical and cognitive fatigue in patients with Crohn's disease: a cross-sectional and longitudinal study. Infl amm Bowel Dis 2014; 20: 115-25.
120. Vogelaar L, van't Spijker A, van Tilburg AJ et al. Determinants of fatigue in Crohn's disease patients. Eur J Gastroenterol Hepatol 2013; 25: 246-51.
121. Yellen SB, Cella DF, Webster K et al. Measuring fatigue and other anemiarelated symptoms with the Functional Assessment of Cancer Th erapy (FACT) measurement system. J Pain Symptom Manage 1997; 13: 63-74.
122. Reilly MC, Gerlier L, Brabant Y et al. Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease. Clin Th er 2008; 30: 393-404.
123. Hoivik ML, Moum B, Solberg IC et al. Work disability in infl ammatory bowel disease patients 10 years aft er disease onset: results from the IBSEN Study. Gut 2013; 62: 368-75.
124. Israeli E, Graff LA, Clara I et al. Low prevalence of disability among patients with infl ammatory bowel diseases a decade aft er diagnosis. Clin Gastroenterol Hepatol 2014; 12: 1330-7.
125. Mandel MD, Balint A, Lovasz BD et al. Work disability and productivity loss in patients with infl ammatory bowel diseases in Hungary in the era of biologics. Eur J Health Econ 2014; 15: S121-8.
126. van der Valk ME, Mangen MJ, Leenders M et al. Risk factors of work disability in patients with infl ammatory bowel disease-a Dutch nationwide web-based survey: work disability in infl ammatory bowel disease. J Crohns Colitis 2014; 8: 590-7.
127. Spiegel BM, Hays RD, Bolus R et al. Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales. Am J Gastroenterol 2014; 109: 1804-14.
128. Colombel JF, Rutgeerts PJ, Sandborn WJ et al. Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol 2014; 12: 414-22.
129. Colombel JF, Reinisch W, Mantzaris GJ et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease-a SONIC post hoc analysis. Aliment Pharmacol Th er 2015; 41: 734-46.
130. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-9.
131. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989; 298: 82-6.
132. Walmsley RS, Ayres RC, Pounder RE et al. A simple clinical colitis activity index. Gut 1998; 43: 29-32.
133. Turner D, Otley AR, Mack D et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007; 133: 423-32.
134. Travis SP, Schnell D, Krzeski P et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012; 61: 535-42.
135. Feagan BG, Rutgeerts P, Sands BE et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710.
136. Panaccione R, Ghosh S, Middleton S et al. Combination therapy with infl iximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014; 146: 392-400.
137. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infl iximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
138. Sandborn WJ, van Assche G, Reinisch W et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-65.
139. Turner D, Seow CH, Greenberg GR et al. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7: 1081-8.
140. Lewis JD, Lichtenstein GR, Deren JJ et al. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology 2008; 134: 688-95.
141. Feagan BG, Reinisch W, Rutgeerts P et al. Th e eff ects of infl iximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007; 102: 794-802.
142. Sandborn WJ, Rutgeerts P, Feagan BG et al. Colectomy rate comparison aft er treatment of ulcerative colitis with placebo or infl iximab. Gastroenterology 2009; 137: 1250-60.
143. Feagan BG, Sandborn WJ, D'Haens G et al. Th e role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology 2013; 145: 149-57.
144. Inoue N, Takabayashi K, Takayama T et al. P215 Endoscopic remission (Mayo score 0 rather than score 1) predicts long-term clinical remission in ulcerative colitis. J Crohns Colitis 2013; 7: S95.
145. Yokoyama K, Kobayashi K, Mukae M et al. Clinical study of the relation between mucosal healing and long-term outcomes in ulcerative colitis. Gastroenterol Res Pract 2013; 2013: 192794.
146. Travis SP, Schnell D, Krzeski P et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology 2013; 145: 987-95.
147. Pola S, Feagan BG, Fahmy M et al. Tu1106 Observer agreement and construct validity in central endoscopic assessment of disease activity in ulcerative colitis. Gastroenterology 2013; 144: S-763.
148. Levesque BG, Loftus EV, Panaccione R et al. P150 responsiveness of endoscopic indices in the evaluation of ulcerative colitis. J Crohns Colitis 2014; 8: S124.
149. Samuel S, Bruining DH, Loftus EV Jr. et al. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol 2013; 11: 49-54.
150. Th ia KT, Loftus EV Jr., Pardi DS et al. Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. Infl amm Bowel Dis 2011; 17: 1257-64.
151. Bitton A, Peppercorn MA, Antonioli DA et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001; 120: 13-20.
152. Riley SA, Mani V, Goodman MJ et al. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991; 32: 174-8.
153. Ordas I, Rimola J, Garcia-Bosch O et al. Diagnostic accuracy of magnetic resonance colonography for the evaluation of disease activity and severity in ulcerative colitis: a prospective study. Gut 2013; 62: 1566-72.
154. Oussalah A, Laurent V, Bruot O et al. Diff usion-weighted magnetic resonance without bowel preparation for detecting colonic infl ammation in infl ammatory bowel disease. Gut 2010; 59: 1056-65.
155. Sands BE, Tremaine WJ, Sandborn WJ et al. Infl iximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Infl amm Bowel Dis 2001; 7: 83-8.
156. Aceituno M, Garcia-Planella E, Heredia C et al. Steroid-refractory ulcerative colitis: predictive factors of response to cyclosporine and validation in an independent cohort. Infl amm Bowel Dis 2008; 14: 347-52.
157. Cacheux W, Seksik P, Lemann M et al. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol 2008; 103: 637-42.
158. Gordon FH, Hamilton MI, Donoghue S et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Th er 2002; 16: 699-705.
159. Henriksen M, Jahnsen J, Lygren I et al. C-reactive protein: a predictive factor and marker of infl ammation in infl ammatory bowel disease. Results from a prospective population-based study. Gut 2008; 57: 1518-23.
160. Kumar S, Ghoshal UC, Aggarwal R et al. Severe ulcerative colitis: prospective study of parameters determining outcome. J Gastroenterol Hepatol 2004; 19: 1247-52.
161. Osada T, Ohkusa T, Okayasu I et al. Correlations among total colonoscopic fi ndings, clinical symptoms, and laboratory markers in ulcerative colitis. J Gastroenterol Hepatol 2008; 23: S262-7.
162. Solem CA, Loftus EV Jr., Tremaine WJ et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in infl ammatory bowel disease. Infl amm Bowel Dis 2005; 11: 707-12.
163. Yoon JY, Park SJ, Hong SP et al. Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis. Dig Dis Sci 2014; 59: 829-37.
164. De Vos M, Louis EJ, Jahnsen J et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infl iximab maintenance therapy. Infl amm Bowel Dis 2013; 19: 2111-7.
165. Molander P, af Bjorkesten CG, Mustonen H et al. Fecal calprotectin concentration predicts outcome in infl ammatory bowel disease aft er induction therapy with TNFalpha blocking agents. Infl amm Bowel Dis 2012; 18: 2011-7.
166. Osterman MT, Aberra FN, Cross R et al. Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2014; 12: 1887-93.
167. Yamamoto T, Shiraki M, Bamba T et al. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy. Int J Colorectal Dis 2014; 29: 485-91.
168. Sandborn WJ, Feagan BG, Marano C et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 96-109.
169. Sandborn WJ, Colombel JF, D'Haens G et al. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Th er 2013; 37: 204-13.
170. Cohen BL, Zoega H, Shah SA et al. Fatigue is highly associated with poor health-related quality of life, disability and depression in newly-diagnosed patients with infl ammatory bowel disease, independent of disease activity. Aliment Pharmacol Th er 2014; 39: 811-22.
171. Sherman M, Tsynman DN, Kim A et al. Sustained improvement in health-related quality of life measures in patients with infl ammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy. J Dig Dis 2014; 15: 174-9.
172. Ardizzone S, Maconi G, Russo A et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006; 55: 47-53.
173. Wright R, Truelove SR. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am J Dig Dis 1966; 11: 847-57.
174. Annese V, Daperno M, Rutter MD et al. European evidence based consensus for endoscopy in infl ammatory bowel disease. J Crohns Colitis 2013; 7: 982-1018.
175. Fengming Y, Jianbing W. Biomarkers of infl ammatory bowel disease. Dis Markers 2014; 2014: 710915.
176. Peyrin-Biroulet L, Billioud V, D'Haens G et al. Development of the Paris defi nition of early Crohn's disease for disease-modifi cation trials: results of an international expert opinion process. Am J Gastroenterol 2012; 107: 1770-6.